Risk factors

Arcosa faces heavy operational exposure to weather seasonality, project delays, raw material price volatility, and stringent environmental regulations across its manufacturing segments.

Accendra Health depends heavily on Vizient, Premier, and HPG GPOs for 65% of net revenue. The company carries $1.9 billion in debt and faces integration and pending risks regarding the Rotech acquisition and potential sale of its Products & Healthcare Services segment.

Archer Aviation is an early-stage company facing substantial accumulated losses and ongoing capital needs to develop its eVTOL aircraft.

International sales, particularly in Asia and China, drive most revenue, exposing Axcelis to significant U.S. export control risks.

Private mortgage insurer facing intense industry competition and strict regulatory capital requirements under PMIERs and state laws.

Public finance distress and municipal defaults threaten insured obligations and potential recoveries.

Company is heavily reliant on Trilogy Manager for its integrated senior health campuses. Operations are concentrated in senior housing and healthcare real estate. Portfolio performance is sensitive to healthcare tenant financial stability and industry regulation.

AHRT's risk profile is dominated by heavy geographical concentration in the Mid-Atlantic region and substantial debt obligations totaling $1.3 billion. The company faces significant exposure to real estate market fluctuations, interest rate volatility, and tenant lease expirations across retail, office, and multifamily assets.

Airship AI faces significant customer concentration, with a single customer driving 57% of 2024 revenue. The company relies heavily on unpatented proprietary technology without holding any patents. Operations are exposed to government budgetary uncertainties, long sales cycles, and a history of net losses.

Aldeyra Therapeutics faces significant risks from reliance on clinical trials, financing needs, manufacturing complexities, and regulatory approvals for product candidates like reproxalap.

Revenue concentration on Invisalign and iTero scanners leaves the company exposed to adoption rates and competitive resistance.

Alkami Technology faces primary risks around rapid growth, intense competition in digital banking solutions for financial institutions, and heavy reliance on Amazon Web Services. The company also highlights risks from its credit facility covenants, potential intellectual property disputes, and the loss of emerging growth company status in December 2024.